Practical considerations for cardiovascular care during COVID-19 pandemic
DOI:
https://doi.org/10.18203/2349-3933.ijam20212306Keywords:
Cardiovascular complications, CV drugs and COVID-19, Older adults, TeleconsultationAbstract
Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a global pandemic affecting billions of lives and posing a stiff challenge to the delivery of routine healthcare across the world. The new second wave of COVID-19 in India presents with higher rate of infection and percentage of asymptomatic and mildly symptomatic cases is much higher than before, which means more people are spreading the disease. People with co-morbidities such as pre-existing cardiovascular conditions are at risk of suffering from severe complications of COVID-19 including acute respiratory distress and multi-organ failure. The pandemic has also resulted in people deferring routine care for conditions such as hypertension, diabetes and other cardiometabolic diseases. Initial reports also linked major CV drug classes such as the angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) to adverse outcomes in COVID-19 patients. While subsequent reports have disproved these earlier findings, the science is rapidly evolving and the information overload has served to confuse general practitioners and consultant physicians alike. This review examined the practical considerations in terms of cardiocascular complications, effect of drugs, older adults and tele-consultation for CV care during COVID-19 pandemic.
References
WHO. Fact sheet: Coronavirus disease 2019 (COVID-19) Situation Report, 2021. Available at: https://cdn.who.int/media/docs/default-source/wrindia/situation-report/india-situation-report-63.pdf?sfvrsn=7d4fae4e_4. Accessed on 11 April 2021.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-74.
Nishiga M, Wang DW, Han Y, Lewis DB, Joseph C Wu. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543-58.
Bansal M. Cardiovascular disease and COVID-19. diabetes and metabolic syndrome: clinical research and reviews. Sci Dir. 2020;14(3):247-50.
Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-43.
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):21.
Ramakrishnan S, Jabir A, Jayagopal PB, Mohanan PP, Nair VK, Das MK, et al. Pattern of acute MI admissions in India during COVID-19 era: a cardiological society of India study-rationale and design. Indian Heart J. 2020;72(6):541-6.
Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-8.
Ryan PM, Caplice N. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response. Open Heart. 2020;7(1):001302.
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020;5(7):831-40.
European Society of Cardiology. Fact sheet: Fear of COVID-19 keeping more than half of heart attack patients away from hospitals. Available at: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Fear-of-COVID-19-keeping-more-than-half-of-heart-attack-patients-away-from-hospitals. Accessed on 11 April 2021.
Alexander T, Thomson VS, Malviya A, Mohan B, Wander GS, Harikrishnan S, et al. Guidance for health care providers on management of cardiovascular complications in patients suspected or confirmed with covid 19 virus infection. J Assoc Physicians India. 2020;68(5):46-9.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239-42.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574-81.
Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of COVID-19 in New York City. N Engl J Med. 2020;382(24):2372-4.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9.
Pinto-Sietsma SJ, Flossdorf M, Buchholz VR, Offerhaus J, Bleijendaal H, Beudel M, et al. Antihypertensive drugs in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):415-6.
Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970-6.
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605-10.
Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID‐19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):016219.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875-9.
Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364-74.
Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757-60.
Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) infection and renin angiotensin system blockers. JAMA Cardiol. 2020;5(7):745-7.
Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV-2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801-3.
Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705-14.
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382:2431-40.
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382:2441-8.
Bozkurt B, Kovacs R, Harrinton, B. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Card Fail. 2020;26(5):370.
European Society of Cardiology. Fact sheet: Position statement of the ESC council on hypertension on ACE-inhibitors and angiotensin receptor blockers, 2020. Availabe at: https://www.escardio.org/ Councils/Council-on-Hypertension-(CHT)/News/ position-statement-of-the-esc-council-on-hypert-ension-on-ace-inhibitors-and-ang. Accessed on 11 April 2021.
Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology. Scientific statement on using of renin angiotensin system blockers in patients with cardiovascular disease and COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):014.
Kerkar P, Naik N, Alexander T, Bahl VK, Chakraborty RN, Chatterjee SS, et al. Cardiological society of India: document on acute MI care during COVID-19. Indian Heart J. 2020;72(2):70-4.
Bansal S, Agstam S, Gupta A, Gupta P, Isser HS. Continue ACE inhibitors/ARB'S till further evidence in coronavirus disease 2019 (COVID-19). Indian Heart J. 2020;72(3):212-3.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-36.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
Jankelson L, Karam G, Becker ML, Chinitz LA, Tsai MC. QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. Heart Rhythm. 2020;17(9):1472-9.
Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020;382:2411-8.
US FDA. Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734™). Available at: https://www.fda.gov/ media/137566/download. Accessed on 11 April 2021.
US FDA. News Release. FDA Approves First Treatment for COVID-19, 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19. Accessed on 11 April 2021.
Yuan S. Statins may decrease the fatality rate of Middle East respiratory syndrome infection. mBio. 2015;6(4):01120.
Brett SJ, Myles P, Lim WS, Enstone JE, Bannister B, Semple MG, et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One. 2011;6(4):18120.
Bianconi V, Violi F, Fallarino F, Pignatelli P, Sahebkar A, Pirro M. Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19? Drugs. 2020;80(14):1383-96.
Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, et al. Aspirin use is associated with decreased mechanical ventilation, icu admission and in-hospital mortality in hospitalized patients with COVID-19. Anesth Analg. 2021;132(4):930-41.
Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020;6:260-1.
American College of Cardiology. Fact sheet: Strategies for risk reduction and management of older adults with cardiovascular disease during the COVID-19 pandemic, 2020. Available at: https://www.acc.org/latest-in-cardiology/articles/ 2020/04/22/20/42/strategies-for-risk-reduction-and-management-of-older-adults-with-cardiovascular-disease-during-the-coronavirus-disease-2019-covid-19-pandemic. Accessed on 12 April 2021.
Ghosh A, Gupta R, Misra A. Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: guidelines for physicians. Diabetes Metab Syndr. 2020;14(4):2736.
Ministry of Health and Family Welfare. Fact sheet: Telemedicine practice guidelines enabling registered medical practitioners to provide healthcare using telemedicine, 2020. Available at: https://www. mohfw.gov.in/pdf/Telemedicine.pdf. Accessed on 12 April 2021.
Ghosh AK, Joshi S, Ghosh A. Effective patient-physician communication: a concise review. J Assoc Physicians India. 2020;68(6):53-7.
